Bellicum Pharmaceuticals Inc
(NASDAQ : BLCM)

( )
BLCM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$803.98m
AMGNAmgen Inc.
-0.76%185.501.2%$628.99m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$482.29m
BIIBBiogen Inc.
-4.17%321.171.3%$427.44m
ILMNIllumina, Inc.
-1.77%296.883.5%$311.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$290.18m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$253.58m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$219.68m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$152.33m
AAgilent Technologies, Inc.
-0.83%77.911.6%$150.84m
EXASExact Sciences Corporation
-0.42%83.2825.3%$132.28m
INCYIncyte Corporation
-0.49%83.332.5%$111.93m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$108.01m
EXELExelixis, Inc.
-0.09%21.226.4%$82.07m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$77.22m

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.